
Table of Contents

16.2 SUBJECT DATA LISTINGS

- 16.2.1 Discontinued Subjects
- 16.2.2 Protocol Deviations
- 16.2.3 Subjects Excluded From the Efficacy Analysis
- 16.2.4 Demographic Data and Other Baseline Characteristics
- 16.2.5 Compliance and/or Drug Concentration Data
- 16.2.6 Individual Clinical Data (Primary Endpoints)
- 16.2.7 Adverse Event Listings
- 16.2.8 Listing of Individual Laboratory Measurements by Subject

16.2 SUBJECT DATA LISTINGS

16.2.1 Discontinued Subjects

Listing 16.2.1-1	Inclusion/exclusion exceptions
Listing 16.2.1-2	Disposition
Listing 16.2.1-3	Subject visits
Listing 16.2.1-4	Trial elements
Listing 16.2.1-5	Trial arms
Listing 16.2.1-6	Trial visits

Listing 16.2.1-1 Inclusion/exclusion exceptions

(b) (4)

CONFIDENTIAL


(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL


(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



Listing 16.2.1-3 Subject visits

(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)




(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL


(b) (4)




Listing 16.2.1-4 Trial elements

(b) (4)

Listing 16.2.1-5 Trial arms



(b) (4)



(b) (4)



Listing 16.2.1-6 Trial visits

(b) (4)



CONFIDENTIAL

(b) (4)



16.2.2 Protocol Deviations

Listing 16.2.2-1 Protocol deviations

Listing 16.2.2-1 Protocol deviations

(b) (4)


16.2.3 Subjects Excluded From the Efficacy Analysis

Not applicable.


16.2.4 Demographic Data and Other Baseline Characteristics

Listing 16.2.4-1	Demographics
Listing 16.2.4-2	Medical history
Listing 16.2.4-3	Concomitant medications (duration)
Listing 16.2.4-4	Concomitant medications (indication)

Listing 16.2.4-1 Demographics



Listing 16.2.4-2 Medical history



Listing 16.2.4-3 Concomitant medications (duration)

(b) (4)

CONFIDENTIAL

(b) (4)



Listing 16.2.4-4 Concomitant medications (indication)

(b) (4)

CONFIDENTIAL

(b) (4)




16.2.5 Compliance and/or Drug Concentration Data

[Listing 16.2.5-1](#) [Exposure](#)

Listing 16.2.5-1 Exposure

(b) (4)

(b) (4)



(b) (4)



(b) (4)

(b) (4)



(b) (4)


(b) (4)

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)



(b) (4)




(b) (4)

16.2.6 Individual Clinical Data (Primary Endpoints)

[Listing 16.2.6-1](#) [Vital signs](#)
[Listing 16.2.6-2](#) [Questionnaires](#)

Listing 16.2.6-1 Vital signs

(b) (4)



(b) (4)

(b) (4)

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL


(b) (4)

CONFIDENTIAL


(b) (4)

CONFIDENTIAL

(b) (4)




(b) (4)



CONFIDENTIAL

(b) (4)






CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)





(b) (4)



(b) (4)



(b) (4)



(b) (4)




CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)



(b) (4)



CONFIDENTIAL

(b) (4)



(b) (4)



(b) (4)




(b) (4)



CONFIDENTIAL

(b) (4)



(b) (4)



(b) (4)



(b) (4)

(b) (4)




(b) (4)




(b) (4)





(b) (4)




(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)




(b) (4)




(b) (4)




(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)



(b) (4)


Listing 16.2.6-2 Questionnaires

(b) (4)

(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL


(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)



CONFIDENTIAL

(b) (4)



(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

16.2.7 Adverse Event Listings

[Listing 16.2.7-1](#) [Adverse events](#)

Listing 16.2.7-1 Adverse events

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)


CONFIDENTIAL



16.2.8 Listing of Individual Laboratory Measurements by Subject

[Listing 16.2.8-1](#) [Laboratory tests](#)

Listing 16.2.8-1 Laboratory tests



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)


CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL



CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)

CONFIDENTIAL

(b) (4)